PRZOOM - /newswire/ -
Albuquerque, NM, United States, 2010/01/11 - Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) will present information on its proprietary CyPath® diagnostic assay for the detection of early-stage lung cancer at the OneMedPlace Finance Forum on Tuesday, Jan. 12, in San Francisco.
The OneMedPlace Finance Forum connects emerging companies in the healthcare and life science industries with investors and strategic partners that can help bring new technologies to the marketplace.
“We are delighted to have the opportunity to showcase our technology before a large number of qualified investors who operate specifically in the healthcare sector. This audience is going to immediately understand the market potential for a non-invasive, inexpensive and accurate screening tool for lung cancer,” said Biomoda President and Chief Executive Officer John Cousins.
Currently in clinical trials, the Biomoda diagnostic is a porphyrin application originally developed at the Los Alamos National Laboratory that preferentially binds to cancerous or aberrant cells extracted from deep lung sputum samples. Cancerous cells treated with Biomoda’s patented CyPath® labeling solution fluoresce red under ultraviolet light. Until the diagnostic receives FDA approval, it may be used for investigational purposes only.
“Lung cancer is the deadliest cancer, primarily because it is too often diagnosed in the late stages when it has metastasized beyond the lungs,” Cousins said. “A screening technology that can identify cancer at the cellular level has the potential to save hundreds of thousands of lives. That’s the message we are taking to the OneMedPlace Forum.”
Biomoda (biomoda.com) is one of 114 companies presenting over the two-day conference Jan. 12-13 at the Sir Francis Drake Hotel in San Francisco. In addition to company presentations, panels made up of leading investors, analysts, business development executives, CEOs and clinical opinion leaders will address advances in six therapeutic areas: oncology, obesity and metabolic disorders, diagnostics and personalized medicine, neurology, cardiology, and ophthalmology.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are made as of the date of this press release and are subject to change without notice.